Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Somsak Bhitiyakul

Nephrology Kingston, NY Medical Doctor

NPI 1366547663 CMS profile 1085488

368 Broadway, Suite 201, Kingston, NY 12401

Open in the dashboard

General payments

$1,373

79 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Somsak Bhitiyakul of Kingston, NY is reported in the CMS Open Payments database as having received $1,373 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $527 30
2020 General $392 22
2019 General $454 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Somsak Bhitiyakul
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Somsak Bhitiyakul were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Somsak Bhitiyakul Nephrology median Middle half National median
2019 $454 $236 $90–$588 $163
2020 $392 $135 $46–$364 $114
2021 $527 $202 $67–$551 $132
2022 $0 $242 $77–$695 $149
2023 $0 $254 $84–$766 $160
2024 $0 $300 $99–$852 $164
2025 $0 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $348 21 payments
  2. Novo Nordisk Inc $218 13 payments
  3. Janssen Pharmaceuticals, Inc $213 10 payments
  4. Amarin Pharma Inc. $121 7 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $80 4 payments
  6. Fresenius USA Marketing, Inc. $74 5 payments
  7. Lilly USA, LLC $60 4 payments
  8. Arbor Pharmaceuticals, Inc. $47 3 payments
  9. Amgen Inc. $47 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $39 2 payments
  11. Other $126 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $1,373 79 payments
Products named General payments · program years 2019–2021
  1. FARXIGA $311 19 payments
  2. Ozempic $218 13 payments
  3. XARELTO $213 10 payments
  4. RYBELSUS $201 12 payments
  5. INVOKANA $159 8 payments
  6. Vascepa Cardiovascular $74 4 payments
  7. Velphoro $74 5 payments
  8. JARDIANCE Diabetes $65 3 payments
  9. JARDIANCE Diabetes $60 4 payments
  10. Vascepa Hypertriglyceridemia $47 3 payments
  11. Other $501 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record